Alpha-Glucosidase Inhibitors (AGIs): A New Class of Oral Medication for Treatment of Type 2 Diabetes Patients

Devajit Mohajan and Haradhan Kumar Mohajan
Additional contact information
Devajit Mohajan: Department of Civil Engineering, Chittagong University of Engineering & Technology, Chittagong, Bangladesh
Haradhan Kumar Mohajan: Department of Mathematics, Premier University, Chittagong, Bangladesh

Journal of Innovations in Medical Research, 2024, vol. 3, issue 4, 1-6

Abstract: α-Glucosidase inhibitors (AGIs) are a new class of antidiabetic drug that inhibits the absorption of carbohydrates from the gut and is exclusively used for the treatment of T2D. This group lowers blood glucose in a dose-dependent fashion by modifying the intestinal absorption of carbohydrates and fat. For T2D patients, postprandial hyperglycaemia control is essential for the maintaining recommended HbA1c goals, and AGIs are used as monotherapy or in combination with other antidiabetic medications to achieve normal glucose level. Acarbose, Miglitole, 1-deoxynojirimycin, and Voglibose are four AGIs, and among these; Acarbose has been shown to decrease the risk of progressing to diabetes in subjects with impaired glucose tolerance. In this mini review an attempt has been taken to discuss the aspects of AGIs with their efficacy and safety when a T2D patient uses these.

Keywords: α-Glucosidase inhibitors; α-glucosidase enzyme; hyperglycaemia (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.paradigmpress.org/jimr/article/view/1381/1215 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bdz:joimer:v:3:y:2024:i:4:p:1-6

DOI: 10.56397/JIMR/2024.12.01

Access Statistics for this article

More articles in Journal of Innovations in Medical Research from Paradigm Academic Press
Bibliographic data for series maintained by Editorial Office ().